JOSE ROBERTO FILASSI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
19 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 19
- Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer(2014) RICCI, Marcos Desídérío; FORMIGONI, Maria Carolina; ZULIANI, Lucia Maria Martins; AOKI, Denis Seiiti; MOTA, Bruna Salani; FILASSI, José Roberto; PIATO, José Roberto Morales; BARACAT, Edmund ChadaPURPOSE: To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen. METHODS: We performed a retrospective cohort study in order to correlate any variation in the body mass index before and after adjuvant chemotherapy with patient's age and adjuvant chemotherapy regimen. Patients who received any form of prior hormone therapy, such as tamoxifen or aromatase inhibitors, were excluded. We selected data for 196 patients with stage I to III breast cancer who were treated by radical or conservative surgery and received adjuvant chemotherapy at the Cancer Institute of the State of São Paulo, Brazil. RESULTS: Before adjuvant chemotherapy, 67.8% of patients were classified as overweight or obese according to their body mass indices. Around 66.3% (95% CI 59.7–73.0) of the patients exhibited an increase in the body mass index after adjuvant chemotherapy. The average age of all patients was 56.3±11.3 years. Participants whose body mass index increased were younger than those with no increase (54.7±11.1 versus 59.3±11.2 years; p=0.007). Patients were treated with the following adjuvant chemotherapy regimens: doxorubicin, cyclophosphamide, and paclitaxel (AC-T, 129 patients, 65.8%); 5-fluoracil, doxorubicin, and cyclophosphamide (36 patients, 18.4%); cyclophosphamide, methotrexate, and 5-fluoracil (16 patients, 8.2%); docetaxel and cyclophosphamide (7 patients, 3.6%); and other regimen (8 patients, 4.1%). The AC-T regimen showed a statistically significant association with increase in the body mass index (p<0.001 by ANOVA). CONCLUSIONS: Most patients with breast cancer showed an increase in the body mass index after adjuvant chemotherapy, especially after the AC-T chemotherapy regimen.
conferenceObject Brazilian randomized study - Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI trial)(2018) DORIA, Maira T.; MOTA, Bruna S.; REIS, Yedda N.; RICCI, Marcos D.; PIATO, Jose R. M.; FERREIRA, Vera C. C. S.; SHIMIZU, Carlos; BARROS, Nestor; FILASSI, Jose R.; BARACAT, Edmund C.bookPart Mastite(2013) ROCHA, Fernanda Barbosa Coelho; PIATO, José Roberto Morales; FILASSI, José Roberto; BARACAT, Edmund Chada- EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer(2016) NEUSQUEN, Lucienne Pereira Del Grossi; FILASSI, José Roberto; FRISTACHI, Carlos Elias; CARVALHO, Kátia Candido; DÓRIA, Maíra Teixeira; SOARES JÚNIOR, José Maria; PIATO, José Roberto MoralesAbstract Introduction Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer. However, some tumors will not respond to this treatment due to histological and molecular features. The protein EZH2 (enhancer of zest homolog 2) is a histone methyltransferase that is correlated with poorly differentiated breast carcinomas and aggressive tumor behavior. Purpose The present study evaluated the association between EZH2 expression and response to NAC, and its correlation with HER2 overexpression, estrogen and progesterone receptors (ER, PR) and Ki-67 proliferation index. Methods A total of 60 patients with locally advanced breast cancer treated with NAC were selected for this study. Twenty-three paraffin blocks had not enough material for tissue resection, and were not evaluated. A tissue microarray based in immunohistochemistry (IHC) analysis of EZH2 was performed for the remaining 37 specimens. Patients were divided into two groups based on response to NAC. Results EZH2 expression was significantly associated with markers of poor prognosis such as ER negativity (p = 0.001), PR negativity (p = 0.042) and high Ki-67 proliferation index (p = 0.002). High EZH2 expression was not correlated with the response to NAC. Conclusions Our data suggested that EZH2 protein expression may not correlate with the clinical response to NAC. Other studies with more patients are needed to confirm this observation.
bookPart Câncer de mama localmente avançado: tratamento(2016) PIATO, José Roberto M.; MANO, Max; BARBOSA, Fernanda; FILASSI, José RobertobookPart Doenças Benignas da Mama(2016) RUIZ, Carlos Alberto; PIATO, José Roberto Morales; MAESAKA, Jonathan Yugo; FREITAS, Gabriela Boufelli de; RICCI, Marcos Desidério; FILASSI, José RobertobookPart Abordagem axilar(2019) MAESAKA, Jonathan Yugo; PIATO, José Roberto Morales; FILASSI, José Roberto- Criteria for prediction of metastatic axillary lymph nodes in early-stage breast cancer(2015) OLIVEIRA FILHO, Helio Rubens de; DÓRIA, Maíra Teixeira; PIATO, José Roberto Morales; SOARES JUNIOR, José Maria; FILASSI, José Roberto; BARACAT, Edmund Chada; RICCI, Marcos DesidérioPURPOSE: To estimate the likelihood of axillary lymph node involvement for patients with early-stage breast cancer, based on a variety of clinical and pathological factors. METHODS: A retrospective analysis was done in hospital databases from 1999 to 2007. Two hundred thirty-nine patients were diagnosed with early-stage breast cancer. Predictive factors, such as patient age, tumor size, lymphovascular invasion, histological grade and immunohistochemical subtype were analyzed to identify variables that may be associated with axillary lymph node metastasis. RESULTS: Patients with tumors that are negative for estrogen receptor, progesterone receptor, and HER2 had approximately a 90% lower chance of developing lymph node metastasis than those with luminal A tumors (e.g., ER+ and/or PR+ and HER2-) - Odds Ratio: 0.11; 95% confidence interval: 0.01-0.88; p=0.01. Furthermore, the risk for lymph node metastasis of luminal A tumors seemed to decrease as patient age increased, and it was directly correlated with tumor size. CONCLUSION: The molecular classification of early-stage breast cancer using immunohistochemistry may help predicting the probability of developing axillary lymph node metastasis. Further studies are needed to optimize predictions for nodal involvement, with the aim of aiding the decision-making process for breast cancer treatment.
bookPart Mastalgia(2019) LIMA, Bruno Salvador Sobreira; PIATO, José Roberto Morales; FILASSI, José Roberto- MRI to Predict Nipple Involvement in Breast Cancer Patients(2016) PIATO, Jose Roberto Morales; ANDRADE, Roberta Dantas Jales Alves de; CHALA, Luciano Fernandes; BARROS, Nestor de; MANO, Max Senna; MELITTO, Alexandre Santos; GONCALVES, Rodrigo; SOARES JUNIOR, Jose Maria; BARACAT, Edmund Chada; FILASSI, Jose RobertoOBJECTIVE. The selection of breast cancer patients as candidates for nipple-sparing mastectomy (NSM) is dependent on the preoperative detection of neoplastic involvement of the nipple-areola complex (NAC). This cross-sectional study was designed to evaluate the accuracy of preoperative breast MRI as a noninvasive method to predict neoplastic involvement of the nipple. MATERIALS AND METHODS. We included 165 female breast cancer patients with a surgical plan that included total mastectomy or breast conservation surgery with the removal of the NAC. All patients underwent MRI before surgery on a 1.5-T unit with a 4-channel in vivo dedicated surface breast coil. One radiologist who was blinded to the results of the histologic evaluations of the specimens evaluated the MRI studies. RESULTS. Of the 170 mastectomy specimens evaluated, 37 (21.8%) had neoplastic involvement of the NAC. The MRI findings of enhancement between the index lesion and the NAC and of nipple retraction were considered statistically significant predictors of nipple involvement in breast cancer patients (p < 0.01 and p = 0.01, respectively). The negative predictive value of the combination of these MRI findings was 83.3%. CONCLUSION. Breast MRI is a safe noninvasive method to preoperatively evaluate breast cancer patients eligible for NSM with a high specificity and a high negative predictive value when enhancement between the index lesion and the nipple and nipple retraction are analyzed.